LAUSR

native immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (alemtuzumab). Bone Marrow Transplantation, 48, 186–190. Risitano, A.M., Selleri, C., Serio, B., Torelli, G.F., Kulagin, A., Maury, S., Halter, J., Gupta, V., Bacigalupo, A., Socie, G., Tichelli, A., Schrezenmeier, H., Marsh, J., Passweg, J. & Rotoli, B.; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). (2010) Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. British Journal of Haematology, 148, 791–796. Scheinberg, P., Nunez, O., Weinstein, B., Scheinberg, P., Wu, C.O. & Young, N.S. (2012) Activity of alemtuzumab monotherapy in treatmentnaive, relapsed, and refractory severe acquired aplastic anemia. Blood, 119, 345–354. Willis, F., Marsh, J.C., Bevan, D.H., Killick, S.B., Lucas, G., Griffiths, R., Ouwehand, W., Hale, G., Waldmann, H. & Gordon-Smith, E.C. (2001) The effect of treatment with campath-1H in patients with autoimmune cytopenias. British Journal of Haematology, 114, 891–898. Young, N.S. & Maciejewski, J. (1997) The pathophysiology of acquired aplastic anemia. The New England Journal of Medicine, 336, 1365–1372.